BillionToOne stock
BLLNNASDAQBillionToOne, Inc., HealthcareISIN US0901681058
64Score 64 out of 100, Neutral
Price and trend
80 / 100
Price history
+8.8% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 26% below its 52-week high. Largest decline in 1 year: 51% (November 2025 to March 2026).
Chart figures for advanced users
- SMA 50$106.88
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$97.54
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$64.03
- The lowest closing price of the last twelve months.
- Resistance$149.97
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BillionToOne, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $5.29B, is number 25 of 37 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $457.69M (up 50%) and adjusted earnings per share of $0.94.
- MEQIRI Score 64 out of 100 (Neutral): rank 219 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $30.25, with the price 266% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 26.3% a year through 2028 (estimates from 5 analysts).Growth 50
- More cash than debtCash $561.51M, financial debt $140.45M.Stability 75
- High return on capitalReturn on invested capital 17.2% in fiscal 2025, Medical (Diagnostics & Research) median 6.4%.Profitability 75
Weaknesses
- Above fair valuePrice 266% above the fair value of $30.25.Valuation 13
- Volatile share priceVolatility 87% a year over the last 12 months.
Its standout strengths are capital allocation and technical analysis, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $20.17 and expensive above $60.50 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $30.53 (cash-flow model) and $29.97 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $27.57, at 8.2% it would be $34.19.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 71.9% on the twelve months before. Revenue has grown strongly since 2023, at around 106% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 5%, net 2%. Last 12 months: net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Mar 2027in 110 days
- Last reported
- 4 Nov 2026EPS reported $0.32 (expected $0.15)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.94+21.7%
- Revenue
- $457.69M+0.6%
- Earnings per share
- $0.96−4.2%
- Revenue
- $577.9M+0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −35.6%2026 revenue outlook of $450 million to $465 million (growth of 48% to 52%) reiterated, gross margin still expected at or above 70%.
“We are reiterating our 2026 total revenue outlook of $450 million to $465 million representing growth of approximately 48% to 52% compared to full year 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $49.73M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- ten Bosch John RoderickSale
2 Nov 2026, SVP of Laboratory Operations
- Shares
- 2,834
- Price
- $113.17
- Value
- $320,724
- Atay OguzhanSale
2 Nov 2026, Chairman and CEO
- Shares
- 30,335
- Price
- $109.93
- Value
- $3.33M
- Tsao DavidSale
2 Nov 2026, Chief Technology Officer
- Shares
- 20,000
- Price
- $109.24
- Value
- $2.18M
Show 31 more
- Atay OguzhanSale
28 Oct 2026, Chairman and CEO
- Shares
- 11,000
- Price
- $118.00
- Value
- $1.3M
- Atay OguzhanSale
15 Oct 2026, Chairman and CEO
- Shares
- 5,150
- Price
- $100.23
- Value
- $516,189
- Atay OguzhanSale
14 Oct 2026, Chairman and CEO
- Shares
- 5,850
- Price
- $98.19
- Value
- $574,386
- Atay OguzhanSale
12 Oct 2026, Chairman and CEO
- Shares
- 19,334
- Price
- $94.31
- Value
- $1.82M
- ten Bosch John RoderickSale
5 Oct 2026, SVP of Laboratory Operations
- Shares
- 2,834
- Price
- $105.15
- Value
- $297,995
- Tsao DavidSale
5 Oct 2026, Chief Technology Officer
- Shares
- 20,000
- Price
- $108.15
- Value
- $2.16M
- Atay OguzhanSale
28 Sept 2026, Chairman and CEO
- Shares
- 10,999
- Price
- $120.64
- Value
- $1.33M
- Tsao DavidSale
24 Sept 2026, Chief Technology Officer
- Shares
- 3,333
- Price
- $125.00
- Value
- $416,625
- ten Bosch John RoderickSale
24 Sept 2026, SVP of Laboratory Operations
- Shares
- 1,416
- Price
- $120.00
- Value
- $169,920
- ten Bosch John RoderickSale
21 Sept 2026, SVP of Laboratory Operations
- Shares
- 1,416
- Price
- $106.61
- Value
- $150,960
- Lynch Thomas P.Sale
17 Sept 2026, See Remarks
- Shares
- 35,112
- Price
- $110.33
- Value
- $3.87M
- Atay OguzhanSale
14 Sept 2026, Chairman and CEO
- Shares
- 30,331
- Price
- $99.91
- Value
- $3.03M
- ten Bosch John RoderickSale
9 Sept 2026, SVP of Laboratory Operations
- Shares
- 1,416
- Price
- $97.54
- Value
- $138,117
- Tsao DavidSale
9 Sept 2026, Chief Technology Officer
- Shares
- 20,000
- Price
- $98.77
- Value
- $1.98M
- Lynch Thomas P.Sale
8 Sept 2026, See Remarks
- Shares
- 20,000
- Price
- $99.99
- Value
- $2M
- Tsao DavidSale
25 Aug 2026, Chief Technology Officer
- Shares
- 10,000
- Price
- $100.00
- Value
- $1M
- ten Bosch John RoderickSale
25 Aug 2026, SVP of Laboratory Operations
- Shares
- 1,417
- Price
- $100.00
- Value
- $141,700
- ten Bosch John RoderickSale
10 Aug 2026, SVP of Laboratory Operations
- Shares
- 1,417
- Price
- $92.86
- Value
- $131,583
- Tsao DavidSale
10 Aug 2026, Chief Technology Officer
- Shares
- 10,000
- Price
- $92.86
- Value
- $928,600
- Atay OguzhanSale
5 Aug 2026, Chairman and CEO
- Shares
- 15,539
- Price
- $150.03
- Value
- $2.33M
- Atay OguzhanSale
3 Aug 2026, Chairman and CEO
- Shares
- 45,000
- Price
- $137.07
- Value
- $6.17M
- Sakakibara Shan RikuSale
31 Jul 2026, Chief Product Officer
- Shares
- 4,000
- Price
- $140.21
- Value
- $560,840
- Johnson Nancy JoAnnSale
16 Jul 2026, See Remarks
- Shares
- 14,199
- Price
- $128.29
- Value
- $1.82M
- ten Bosch John RoderickSale
13 Jul 2026, SVP of Laboratory Operations
- Shares
- 4,251
- Price
- $125.46
- Value
- $533,330
- Tsao DavidSale
13 Jul 2026, Chief Technology Officer
- Shares
- 20,000
- Price
- $124.88
- Value
- $2.5M
- Atay OguzhanSale
9 Jul 2026, Chairman and CEO
- Shares
- 12,500
- Price
- $126.10
- Value
- $1.58M
- Sakakibara Shan RikuSale
9 Jul 2026, Chief Product Officer
- Shares
- 8,000
- Price
- $125.00
- Value
- $1M
- Atay OguzhanSale
6 Jul 2026, Chairman and CEO
- Shares
- 38,750
- Price
- $122.05
- Value
- $4.73M
- Johnson Nancy JoAnnSale
1 Jul 2026, See Remarks
- Shares
- 801
- Price
- $124.91
- Value
- $100,056
- ten Bosch John RoderickSale
29 Jun 2026, SVP of Laboratory Operations
- Shares
- 1,416
- Price
- $120.00
- Value
- $169,920
- Sakakibara Shan RikuSale
24 Jun 2026, Chief Product Officer
- Shares
- 4,000
- Price
- $110.00
- Value
- $440,000
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BillionToOne
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 64
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- QiagenQGEN $10.35B75
- RadNetRDNT $5.98B44
- GRAILGRAL $5.46B43
- DiaSorinDIA.MI $5.3B67
- Sotera HealthSHC $4.65B54
- CareDxCDNA $4.19B59
- Vimian GroupVIMIAN.ST $2.23B58
- NeoGenomicsNEO $2.15B39
ETFs that hold BillionToOne
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.70% | 0.50% | €127.64M |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.